PHASE I STUDY OF TRIAPINE IN COMBINATION WITH DOXORUBICIN IN REFRACTORY TUMORS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究不再招募受试者。 (摘自www.Clinicaltrials.gov网站) 化疗中使用的药物，如阿霉素，以不同的方式阻止肿瘤细胞分裂，从而停止生长或死亡。曲拉平(3-AP)可能通过阻断肿瘤细胞生长所需的酶来阻止肿瘤细胞的生长，并可能通过使更多的癌细胞对药物更敏感来帮助阿霉素杀死更多的癌细胞。 这项I期试验正在研究曲拉平和阿霉素治疗转移性或难治性实体肿瘤患者的副作用和最佳剂量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is no longer recruiting subjects. (from www.ClinicalTrials.gov website) Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Triapine (3-AP) may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help doxorubicin kill more cancer cells by making them more sensitive to the drug. This Phase I trial is studying the side-effects and best dose of triapine and doxorubicin in treating patients with metastatic or refractory solid tumors.